CGM Frequency and Glycemic Control: What the Data Shows in Type 2 Diabetes

In this episode, 'CGM Frequency and Glycemic Control: What the Data Shows in Type 2 Diabetes,' the diabetes and managed care experts explore the following question:

1. What is the relationship between HbA1c levels and frequency of continuous glucose monitoring (CGM) use?

Estay Greene and Victoria Bouhairie examined findings from a retrospective cross-sectional study of adults with type 2 diabetes diagnosed, exploring how CGM usage frequency correlated with HbA1c reductions across different treatment regimens including GLP-1s, SGLT-2 inhibitors, and insulin therapies. The discussion highlighted that patients in the highest frequency group (those using CGM more than 270 days per year) demonstrated the strongest glycemic improvements across all medication categories, underscoring the value of consistent device engagement. Overall, the data reinforced that higher CGM usage frequency is associated with meaningfully better glycemic outcomes regardless of the treatment regimen.
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
The next episode in this series, 'Clinical Takeaways from CGM Data: Engagement, Technology Fatigue, and Follow-Up,' features the panelists advancing their conversation on diabetes and focusing on key clinical takeaways from the study and best practices for structured follow-up after CGM initiation.